Cancer Stem Cell Niche in Colorectal Cancer and Targeted Therapies

Author(s): Hao Wang, Guihua Cui, Bo Yu, Meiyan Sun, Hong Yang*.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 17 , 2020

Become EABM
Become Reviewer

Abstract:

Cancer stem cells (CSCs), also known as tumor-initiating cells, are a sub-population of tumor cells found in many human cancers that are endowed with self-renewal and pluripotency. CSCs may be more resistant to conventional anticancer therapies than average cancer cells, as they can easily escape the cytotoxic effects of standard chemotherapy, thereby resulting in tumor relapse. Despite significant progress in related research, effective elimination of CSCs remains an unmet clinical need. CSCs are localized in a specialized microenvironment termed the niche, which plays a pivotal role in cancer multidrug resistance. The niche components of CSCs, such as the extracellular matrix, also physically shelter CSCs from therapeutic agents. Colorectal cancer is the most common malignancy worldwide and presents a relatively transparent process of cancer initiation and development, making it an ideal model for CSC niche research. Here, we review recent advances in the field of CSCs using colorectal cancer as an example to illustrate the potential therapeutic value of targeting the CSC niche. These findings not only provide a novel theoretical basis for in-depth discussions on tumor occurrence, development, and prognosis evaluation, but also offer new strategies for the targeted treatment of cancer.

Keywords: Cancer stem cells, multidrug resistance, cancer niche, targeted therapy, chemotherapy, tumor-initiating cells.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 17
Year: 2020
Page: [1979 - 1993]
Pages: 15
DOI: 10.2174/1381612826666200408102305
Price: $95

Article Metrics

PDF: 5